A popular new class of migraine drugs available on the NHS may be linked to an increased risk of miscarriage when used during early pregnancy, according to concerning new research presented at the American Headache Society (AHS) Annual Meeting in Florida.
The medications, known as calcitonin gene-related peptide (CGRP) monoclonal antibodies, have been hailed as a major breakthrough in migraine treatment. Designed to target a protein involved in triggering migraine attacks, the injections have helped thousands of patients who previously struggled to find effective relief. Clinical studies have shown that the treatment can reduce the frequency of migraines in around 50 percent of patients, making it one of the most significant advances in the field in recent years.
However, researchers are now warning that the drugs may pose risks for women who become pregnant while taking them.
The study examined data from 7,579 pregnancies involving 7,119 women between the ages of 15 and 45 who had been diagnosed with migraines before pregnancy. Researchers sought to determine whether there were differences in pregnancy outcomes among women using various migraine treatments during the early stages of pregnancy.
To conduct the analysis, the researchers divided participants into three groups. One group consisted of women taking CGRP monoclonal antibody injections, another included women using propranolol, a beta-blocker commonly prescribed to prevent migraines, and the third group included women who were not taking migraine medication.
The findings revealed a notable increase in miscarriage rates among women who were using CGRP monoclonal antibodies during the critical period between eight and 12 weeks of pregnancy. According to the researchers, miscarriage rates were significantly higher in this group than among women taking alternative treatments or no medication at all.
Overall, approximately five percent of women using CGRP monoclonal antibodies experienced a miscarriage, compared with around two percent of women taking propranolol. Based on the data, researchers estimated that the newer migraine treatment was associated with a 45 percent higher risk of miscarriage during early pregnancy.
While the study does not prove that the medication directly causes miscarriages, the findings raise concerns about potential risks that warrant further investigation. Researchers stressed that additional studies will be needed to better understand the relationship between the drugs and pregnancy outcomes.
The results are particularly important because CGRP monoclonal antibodies have become increasingly popular among migraine sufferers. Many patients who have failed to respond to traditional treatments have turned to the injections as a more effective option for preventing debilitating headaches.
Migraines affect millions of people worldwide and are especially common among women of childbearing age. Severe migraines can have a major impact on daily life, affecting work, family responsibilities, and overall wellbeing. As a result, effective treatments are often considered life-changing by those who suffer from frequent attacks.
Current NHS guidance already advises that women who are pregnant, planning to become pregnant, or trying for a baby should avoid using CGRP monoclonal antibody treatments. The latest findings appear to support that recommendation and may encourage healthcare professionals to discuss pregnancy risks more thoroughly with patients before prescribing the medication.
Medical experts emphasize that women should not stop taking prescribed medications without first consulting their doctor. Anyone currently using CGRP monoclonal antibodies and considering pregnancy is advised to speak with their healthcare provider about alternative treatment options and appropriate timing for discontinuing the medication.
As the use of these innovative migraine treatments continues to grow, researchers say monitoring their long-term safety remains essential. The new findings are likely to prompt further studies aimed at determining whether the increased miscarriage risk is directly linked to the drugs and whether certain patients may be more vulnerable than others.
For now, the research serves as an important reminder that even promising medical breakthroughs can carry potential risks, particularly during pregnancy, when the safety of both mother and baby must be carefully considered.
Emily Johnson is a critically acclaimed essayist and novelist known for her thought-provoking works centered on feminism, women’s rights, and modern relationships. Born and raised in Portland, Oregon, Emily grew up with a deep love of books, often spending her afternoons at her local library. She went on to study literature and gender studies at UCLA, where she became deeply involved in activism and began publishing essays in campus journals. Her debut essay collection, Voices Unbound, struck a chord with readers nationwide for its fearless exploration of gender dynamics, identity, and the challenges faced by women in contemporary society. Emily later transitioned into fiction, writing novels that balance compelling storytelling with social commentary. Her protagonists are often strong, multidimensional women navigating love, ambition, and the struggles of everyday life, making her a favorite among readers who crave authentic, relatable narratives. Critics praise her ability to merge personal intimacy with universal themes. Off the page, Emily is an advocate for women in publishing, leading workshops that encourage young female writers to embrace their voices. She lives in Seattle with her partner and two rescue cats, where she continues to write, teach, and inspire a new generation of storytellers.
